These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 19355801)

  • 21. Overactive bladder medication adherence when medication is free to patients.
    Sears CL; Lewis C; Noel K; Albright TS; Fischer JR
    J Urol; 2010 Mar; 183(3):1077-81. PubMed ID: 20092838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistence and compliance with medication management in the treatment of overactive bladder.
    Kim TH; Lee KS
    Investig Clin Urol; 2016 Mar; 57(2):84-93. PubMed ID: 26981589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persistence with antimuscarinic therapy in patients with overactive bladder.
    Haab F; Castro-Diaz D
    Int J Clin Pract; 2005 Aug; 59(8):931-7. PubMed ID: 16033615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fesoterodine: a new agent for treating overactive bladder.
    Ellsworth P; Berriman SJ; Brodsky M
    Am J Manag Care; 2009 Mar; 15(4 Suppl):S115-7. PubMed ID: 19355800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can we predict which patient will fail drug treatment for overactive bladder? A think tank discussion.
    Nitti VW; Kopp Z; Lin AT; Moore KH; Oefelein M; Mills IW
    Neurourol Urodyn; 2010 Apr; 29(4):652-7. PubMed ID: 20432330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Qualitative Analysis of Factors Influencing Patient Persistence and Adherence to Prescribed Overactive Bladder Medication in UK Primary Care.
    Ali M; Grogan S; Powell S; Staniford L; Nazir J; Landeira M; Covernton PJO; Jaggi A; Fatoye F; Holt M
    Adv Ther; 2019 Nov; 36(11):3110-3122. PubMed ID: 31559603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder.
    Liu HT; Chancellor MB; Kuo HC
    BJU Int; 2009 Jun; 103(12):1668-72. PubMed ID: 19220267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study.
    Dwyer P; Kelleher C; Young J; Haab F; Lheritier K; Ariely R; Ebinger U
    Neurourol Urodyn; 2008; 27(6):540-7. PubMed ID: 18663723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Potentially Inappropriate Use of Antimuscarinic Medications on Healthcare Use and Cost in Individuals with Overactive Bladder.
    Suehs BT; Davis C; Franks B; Yuran TE; Ng D; Bradt J; Knispel J; Vassilakis M; Berner T
    J Am Geriatr Soc; 2016 Apr; 64(4):779-87. PubMed ID: 27059714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overactive bladder: a better understanding of pathophysiology, diagnosis and management.
    Wein AJ; Rackley RR
    J Urol; 2006 Mar; 175(3 Pt 2):S5-10. PubMed ID: 16458739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel uses for antidiuresis.
    Hashim H; Abrams P
    Int J Clin Pract Suppl; 2007 Sep; (155):32-6. PubMed ID: 17727577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimuscarinic mechanisms and the overactive detrusor: an update.
    Andersson KE
    Eur Urol; 2011 Mar; 59(3):377-86. PubMed ID: 21168951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bother related to bladder control and health care seeking behavior in adults in the United States.
    Benner JS; Becker R; Fanning K; Jumadilova Z; Bavendam T; Brubaker L;
    J Urol; 2009 Jun; 181(6):2591-8. PubMed ID: 19375096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Local effects of antimuscarinics.
    Masuda H; Kim YT; Tyagi S; Chancellor MB; de Miguel F; Yoshimura N
    Urol Clin North Am; 2006 Nov; 33(4):511-8, ix-x. PubMed ID: 17011387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. "We have to stop again?!": The impact of overactive bladder on family members.
    Coyne KS; Matza LS; Brewster-Jordan J
    Neurourol Urodyn; 2009; 28(8):969-75. PubMed ID: 19301410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overactive bladder: diagnosis and treatment.
    Vij M; Robinson D; Cardozo L
    Womens Health (Lond); 2010 Mar; 6(2):297-310. PubMed ID: 20187733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The total economic burden of overactive bladder in the United States: a disease-specific approach.
    Onukwugha E; Zuckerman IH; McNally D; Coyne KS; Vats V; Mullins CD
    Am J Manag Care; 2009 Mar; 15(4 Suppl):S90-7. PubMed ID: 19355803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolution of transdermal oxybutynin in the treatment of overactive bladder.
    Sahai A; Mallina R; Dowson C; Larner T; Khan MS
    Int J Clin Pract; 2008 Jan; 62(1):167-70. PubMed ID: 18173821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication.
    Klutke CG; Burgio KL; Wyman JF; Guan Z; Sun F; Berriman S; Bavendam T
    J Urol; 2009 Jun; 181(6):2599-607. PubMed ID: 19375110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interventions do not enhance medication persistence and compliance in patients with overactive bladder: a 24 weeks, randomised, open-label, multi-center trial.
    Sung HH; Han DH; Kim TH; Lee YS; Lee HN; Seo JT; Choo MS; Lee KS
    Int J Clin Pract; 2015 Nov; 69(11):1309-15. PubMed ID: 26215431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.